Cargando…

Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors

Edema Factor (EF) is a component of Bacillus anthracis toxin essential for virulence. Its adenylyl cyclase activity is induced by complexation with the ubiquitous eukaryotic cellular protein, calmodulin (CaM). EF and its complexes with CaM, nucleotides and/or ions, have been extensively characterize...

Descripción completa

Detalles Bibliográficos
Autores principales: Laine, Élodie, Martínez, Leandro, Ladant, Daniel, Malliavin, Thérèse, Blondel, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446745/
https://www.ncbi.nlm.nih.gov/pubmed/23012649
http://dx.doi.org/10.3390/toxins4080580
_version_ 1782244013556891648
author Laine, Élodie
Martínez, Leandro
Ladant, Daniel
Malliavin, Thérèse
Blondel, Arnaud
author_facet Laine, Élodie
Martínez, Leandro
Ladant, Daniel
Malliavin, Thérèse
Blondel, Arnaud
author_sort Laine, Élodie
collection PubMed
description Edema Factor (EF) is a component of Bacillus anthracis toxin essential for virulence. Its adenylyl cyclase activity is induced by complexation with the ubiquitous eukaryotic cellular protein, calmodulin (CaM). EF and its complexes with CaM, nucleotides and/or ions, have been extensively characterized by X-ray crystallography. Those structural data allowed molecular simulations analysis of various aspects of EF action mechanism, including the delineation of EF and CaM domains through their association energetics, the impact of calcium binding on CaM, and the role of catalytic site ions. Furthermore, a transition path connecting the free inactive form to the CaM-complexed active form of EF was built to model the activation mechanism in an attempt to define an inhibition strategy. The cavities at the surface of EF were determined for each path intermediate to identify potential sites where the binding of a ligand could block activation. A non-catalytic cavity (allosteric) was found to shrink rapidly at early stages of the path and was chosen to perform virtual screening. Amongst 18 compounds selected in silico and tested in an enzymatic assay, 6 thiophen ureidoacid derivatives formed a new family of EF allosteric inhibitors with IC50 as low as 2 micromolars.
format Online
Article
Text
id pubmed-3446745
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-34467452012-09-25 Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors Laine, Élodie Martínez, Leandro Ladant, Daniel Malliavin, Thérèse Blondel, Arnaud Toxins (Basel) Review Edema Factor (EF) is a component of Bacillus anthracis toxin essential for virulence. Its adenylyl cyclase activity is induced by complexation with the ubiquitous eukaryotic cellular protein, calmodulin (CaM). EF and its complexes with CaM, nucleotides and/or ions, have been extensively characterized by X-ray crystallography. Those structural data allowed molecular simulations analysis of various aspects of EF action mechanism, including the delineation of EF and CaM domains through their association energetics, the impact of calcium binding on CaM, and the role of catalytic site ions. Furthermore, a transition path connecting the free inactive form to the CaM-complexed active form of EF was built to model the activation mechanism in an attempt to define an inhibition strategy. The cavities at the surface of EF were determined for each path intermediate to identify potential sites where the binding of a ligand could block activation. A non-catalytic cavity (allosteric) was found to shrink rapidly at early stages of the path and was chosen to perform virtual screening. Amongst 18 compounds selected in silico and tested in an enzymatic assay, 6 thiophen ureidoacid derivatives formed a new family of EF allosteric inhibitors with IC50 as low as 2 micromolars. MDPI 2012-07-31 /pmc/articles/PMC3446745/ /pubmed/23012649 http://dx.doi.org/10.3390/toxins4080580 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Laine, Élodie
Martínez, Leandro
Ladant, Daniel
Malliavin, Thérèse
Blondel, Arnaud
Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors
title Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors
title_full Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors
title_fullStr Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors
title_full_unstemmed Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors
title_short Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors
title_sort molecular motions as a drug target: mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446745/
https://www.ncbi.nlm.nih.gov/pubmed/23012649
http://dx.doi.org/10.3390/toxins4080580
work_keys_str_mv AT laineelodie molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors
AT martinezleandro molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors
AT ladantdaniel molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors
AT malliavintherese molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors
AT blondelarnaud molecularmotionsasadrugtargetmechanisticsimulationsofanthraxtoxinedemafactorfunctionledtothediscoveryofnovelallostericinhibitors